Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

To understand how the Mayo Clinic became a superior healthcare brand, I talked with Leonard Berry, PhD, to understand their ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

IT services company DXC Technology reported a third-profit on Tuesday that beat Wall Street estimates, driven by strong enterprise spending on its cloud-based solutions. As the adoption of artificial ...

WALTHAM, MASSACHUSETTS / ACCESS Newswire / February 4, 2025 / Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

The company said Tuesday that Grimace will reunite with his Irish uncle, Uncle O'Grimacey, bringing the mascot out of ...

These sensational income stocks -- sporting an average yield of 6.15% -- can fatten investors' pocketbooks for a long time to ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.